General AML

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML


At the 2018 American Society of Hematology meeting, David A. Sallman from H. Lee Moffitt Cancer Center and Research Institute, Tampa, US discusses the results from the THINK trial, an open-label phase I study assessing the safety and clinical activity of multiple CYAD‑01 administrations without prior preconditioning in patients with relapsing/refractory (R/R) acute myeloid leukemia (AML).

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
33% of people found this article informative